MYOVIEW (technetium tc-99m tetrofosmin kit)
Myoview is a radioactive diagnostic agent indicated for myocardial perfusion imaging (MPI) under both rest and stress (exercise or pharmacologic) conditions. It is used to delineate regions of reversible myocardial ischemia or infarcted myocardium in patients with known or suspected coronary artery disease. Additionally, Myoview is indicated for the assessment of left ventricular function, specifically left ventricular ejection fraction (LVEF) and wall motion, in patients with known or suspected heart disease.
How MYOVIEW Works
Technetium (99mTc) tetrofosmin is a lipophilic, cationic complex that diffuses passively across cell membranes. It is actively retained within myocardial cells that possess intact mitochondria, serving as a marker for cell viability. Following intravenous injection, the agent is distributed within the myocardium in proportion to regional myocardial perfusion and the presence of viable tissue.
Details
- Status
- Prescription
- First Approved
- 1996-02-09
- Patent Cliff
- 2030
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
MYOVIEW Approval History
What MYOVIEW Treats
4 indicationsMYOVIEW is approved for 4 conditions since its original approval in 1996. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Myocardial Ischemia
- Myocardial Infarction
- Coronary Artery Disease
- Heart Disease
MYOVIEW Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to MYOVIEW
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
MYOVIEW FDA Label Details
Indications & Usage
FDA Label (PDF)MYOVIEW is indicated for the treatment of Myocardial Ischemia; Myocardial Infarction; Coronary Artery Disease; Heart Disease.
MYOVIEW Patents & Exclusivity
Patents (1 active)
Pro Intelligence Preview
Deep insights for MYOVIEW
Revenue Insights
- • Quarterly revenue tracking
- • Historical trend analysis
Patent Timeline
- • Cliff: 2030
- • 1 active patents
Trial Analysis
- • Clinical trial tracking
- • Development stage analysis
Competitive Landscape
- • 20 similar drugs
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.